Company Overview
Snapshot
Founded in April 2009 by Igal Kushnir, RedDress operates with 11–50 employees. The company has raised $42.5M across four funding rounds from six investors.
Business overview
RedDress is a Health Tech & Life Sciences company specializing in regenerative wound care solutions. The company develops ActiGraft, an FDA-cleared technology that enables healthcare providers to create in vitro blood clots from a patient's own blood. These blood clots act as a protective covering, biologic scaffold, and wound microenvironment to support the body's natural wound-healing processes. RedDress serves the healthcare industry, targeting both providers and patients in the medical devices and medical treatment & therapeutics sectors.
Strategic signal
In July 2023, RedDress launched ActiGraft PRO with G-Code reimbursement status for the US wound care market. This development is significant as G-Code reimbursement status facilitates broader access and adoption of the ActiGraft PRO system by healthcare providers, signaling strong market penetration potential and a clear path to revenue growth for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is ActiGraft?
- ActiGraft is an FDA-cleared regenerative wound care solution developed by RedDress. It enables healthcare providers to produce in vitro blood clots from a patient's whole blood to promote natural wound-healing processes.
- When did RedDress secure its most recent funding round?
- RedDress secured a D Round in May 2023. The round included investments from Athoss and HCS Capital
- Has RedDress expanded its market reach in Europe?
- In September 2021, RedDress announced distribution agreements in 12 European countries, expanding the availability of its ActiGraft system.
- What is the significance of the Vizient Innovative Technology Contract for ActiGraft?
- In October 2022, RedDress received a Vizient Innovative Technology Contract for ActiGraft systems. This contract signifies recognition of ActiGraft's potential to improve patient outcomes and its innovative nature within the healthcare purchasing network.
- When did RedDress launch ActiGraft PRO with G-Code reimbursement status?
- RedDress launched ActiGraft PRO with G-Code reimbursement status for the US wound care market in July 2023, facilitating broader access and adoption of the product.